Trafalgar International (GCAN) EBT Growth (1y) (2018 - 2026)
Trafalgar International (GCAN) EBT Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -324.14% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.93% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -8.74% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 70.52% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.69% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 124.00% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.76% |
| Dec 31, 2025 | 879.18% |
| Sep 30, 2025 | 21.80% |
| Jun 30, 2025 | -770.17% |
| Mar 31, 2025 | -132.03% |
| Dec 31, 2024 | 7.50% |
| Sep 30, 2024 | 13.60% |
| Jun 30, 2024 | 0.28% |
| Mar 31, 2024 | -3.58% |
| Dec 31, 2023 | 1.14% |
| Sep 30, 2023 | 48.01% |
| Jun 30, 2023 | 27.82% |
| Mar 31, 2023 | 70.84% |
| Dec 31, 2022 | 75.86% |
| Sep 30, 2022 | 59.26% |
| Jun 30, 2022 | -60.16% |
| Mar 31, 2022 | -28.81% |
| Dec 31, 2021 | 48.71% |
| Sep 30, 2021 | 45.07% |
| Jun 30, 2021 | -103.53% |